The FDA has approved remibrutinib ( Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H 1…
Med Lett Drugs Ther. 2026 Jan 5; 68(1745):3-6 doi:10.58347/tml.2026.1745b
The FDA has approved remibrutinib ( Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H 1 -antihistamine treatment. Remibrutinib is the first oral drug to be approved in the US for this indication.
The FDA is requiring a new warning in the prescription and over-the-counter labels of the oral second-generation H 1 -antihistamines cetirizine ( Zyrtec , and others) and levocetirizine ( Xyzal , and others)…
Med Lett Drugs Ther. 2025 Aug 18; 67(1735):135 doi:10.58347/tml.2025.1735e
The FDA is requiring a new warning in the prescription and over-the-counter labels of the oral second-generation H 1 -antihistamines cetirizine ( Zyrtec , and others) and levocetirizine ( Xyzal , and others) about the risk of severe pruritus following discontinuation of treatment.
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2021 Apr 19; 63(1622):57-64
The choice of drugs for treatment of allergic rhinitis depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Quzyttir (TerSera), an IV formulation of the second-generation H 1 -antihistamine cetirizine, has been approved by the FDA for treatment of acute urticaria in patients ≥6 months old. Oral formulations of…
Med Lett Drugs Ther. 2020 Apr 6; 62(1595):55-6
Quzyttir (TerSera), an IV formulation of the second-generation H 1 -antihistamine cetirizine, has been approved by the FDA for treatment of acute urticaria in patients ≥6 months old. Oral formulations of cetirizine ( Zyrtec , and others) have been for sale over the counter for years. Quzyttir is the first parenteral formulation of a second-generation H 1 -antihistamine to become available in the US; parenteral formulations of two first-generation H 1 -antihistamines, diphenhydramine ( Benadryl , and others) and hydroxyzine ( Vistaril , and others), have been available for many years.
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter…
Med Lett Drugs Ther. 2019 Apr 22; 61(1570):57-60
Patients with seasonal allergies often experience nasal itching and congestion, sneezing, rhinorrhea, and itchy, watery eyes. Oral, intranasal, and ophthalmic preparations are widely available over the counter (OTC) for relief of symptoms. Prescription products for management of allergic rhinitis and allergic conjunctivitis are reviewed separately.
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation…
Med Lett Drugs Ther. 2017 May 8; 59(1520):71-82
Allergic rhinitis can be classified as seasonal, perennial, or episodic. It is often associated with allergic conjunctivitis, rhinosinusitis, and asthma. H 1 -ANTIHISTAMINES — Oral – Oral second-generation H 1 -antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild-to-moderate allergic rhinitis. They are less effective for nasal congestion.
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Treat Guidel Med Lett. 2013 May; 11(129):43-52
The use of drugs to prevent and control symptoms of allergic disorders can be optimized when patients avoid exposure to specific allergens and/or environmental conditions that trigger or worsen their symptoms.
The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and…
Med Lett Drugs Ther. 2012 Oct 29; 54(1402):85-7
The FDA has approved a nasal spray fixed-dose combination ( Dymista – Meda) of the H 1 -antihistamine azelastine ( Astelin, Astepro, and generics) and the corticosteroid fluticasone propionate ( Flonase, and generics) for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old who need both medications for symptomatic relief. It is the first nasal spray to be approved in the US that contains both an H 1 -antihistamine and a corticosteroid.
Fexofenadine ( Allegra , and others) is the most recent second-generation H 1 -antihistamine to become available over the counter (OTC). Cetirizine ( Zyrtec , and others) and loratadine ( Claritin , and…
Med Lett Drugs Ther. 2011 May 30; 53(1365):41
Fexofenadine ( Allegra , and others) is the most recent second-generation H 1 -antihistamine to become available over the counter (OTC). Cetirizine ( Zyrtec , and others) and loratadine ( Claritin , and others) are already available OTC. Cetirizine can be sedating in usual doses. Loratadine can be sedating in higher-than-usual doses. Fexofenadine remains nonsedating even in higher doses.
Bepotastine besilate 1.5% ophthalmic solution ( Bepreve - ISTA Pharmaceuticals), an H 1 -antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in…
Med Lett Drugs Ther. 2010 Feb 8; 52(1331):11-2
Bepotastine besilate 1.5% ophthalmic solution ( Bepreve - ISTA Pharmaceuticals), an H 1 -antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.
A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray ( Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old…
Med Lett Drugs Ther. 2009 Apr 20; 51(1310):29-30
A new formulation of the H1-antihistamine azelastine hydrochloride 0.1% nasal spray ( Astepro - Meda) has been approved by the FDA for treatment of seasonal allergic rhinitis (SAR) in patients ≥12 years old and is being heavily advertised to the public on radio, television and the Internet. All azelastine products require a prescription.
Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity,…
Med Lett Drugs Ther. 2008 Jun 30; 50(1289):51-2
Olopatadine 0.6% nasal spray ( Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity, olopatadine is already marketed for treatment of allergic conjunctivitis in a 0.1% solution as Patanol and in a 0.2% solution as Pataday. Azelastine (Astelin) , another H1-antihistamine with mast-cell stabilizing activity, has been available for intranasal treatment of allergic rhinitis since 1997.
Cetirizine ( Zyrtec , and others) and cetirizine/pseudoephedrine ( Zyrtec-D ) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children.…
Med Lett Drugs Ther. 2008 Jan 14; 50(1277):1
Cetirizine ( Zyrtec , and others) and cetirizine/pseudoephedrine ( Zyrtec-D ) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children. Cetirizine is the second of the second-generation H1-antihistamines to become available over the counter. Loratadine ( Claritin , and others) was the first. Cetirizine has been shown to be more effective than loratadine in suppressing histamine-induced wheals in healthy volunteers ( W Carey et al. Drugs Exp Clin Res 2002; 28:243 ), but no well-controlled clinical trials have established that any second-generation H1-antihistamine is more effective overall than any other ( M Plaut and MD Valentine. N Engl J Med 2005; 353:1934 ). Cetirizine may be mildly sedating in some patients, but it is significantly less sedating than first-generation H1-antihistamines such as diphenhydramine ( Benadryl , and others) or chlorpheniramine ( Chlor-Trimeton , and others), which have been available without a prescription for many years. Its safety in young children is better documented than that of any other first- or second-generation H1-antihistamine ( Treat Guidel Med Lett 2007; 5:71 ). Download U.S. English
Levocetirizine ( Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H 1 -antihistamine cetirizine ( Zyrtec ), has been approved by the FDA for treatment of seasonal and perennial…
Med Lett Drugs Ther. 2007 Dec 3; 49(1275):97-9
Levocetirizine ( Xyzal - UCB/Sanofi-aventis), the active enantiomer of the second-generation H 1 -antihistamine cetirizine ( Zyrtec ), has been approved by the FDA for treatment of seasonal and perennial allergic rhinitis (SAR and PAR) and chronic idiopathic urticaria in adults and children 6 years of age and older. Cetirizine has been approved by the FDA for over-the-counter use and may also become available generically in the US. Levocetirizine has been available in Europe since 2001.
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in…
Treat Guidel Med Lett. 2007 Aug; 5(60):71-80
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, anaphylaxis and asthma (reviewed in Treatment Guidelines 2005; 3:33 and not included here), are prevalent worldwide, especially in industrialized countries. Pharmacologic treatment of these disorders continues to improve in efficacy and safety. In addition to using drugs to prevent and control the symptoms of their allergic diseases, patients should also be instructed to avoid, if possible, specific allergens and/or environmental conditions that trigger or worsen their symptoms.
Montelukast ( Singulair - Merck) is an oral cysteinyl leukotriene D 4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic…
Med Lett Drugs Ther. 2005 Oct 24; 47(1220):87-4
Montelukast ( Singulair - Merck) is an oral cysteinyl leukotriene D 4 receptor antagonist originally marketed for treatment of asthma. It was approved by the FDA in 2003 for treatment of seasonal allergic rhinitis and recently for use in perennial allergic rhinitis in adults and children ≥ 6 months old. Intranasal corticosteroids have generally been considered the most effective drugs available for prevention and treatment of allergic rhinitis.
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.
Treat Guidel Med Lett. 2005 Feb; 3(30):7-14
The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.
Epinastine HCl, an H 1 -receptor antagonist and mast cell stabilizer, has been approved by the FDA for use in a 0.05% ophthalmic solution ( Elestat - Allergan/Inspire) for prevention of itching associated with…
Med Lett Drugs Ther. 2004 Apr 26; 46(1181):35-6
Epinastine HCl, an H 1 -receptor antagonist and mast cell stabilizer, has been approved by the FDA for use in a 0.05% ophthalmic solution ( Elestat - Allergan/Inspire) for prevention of itching associated with allergic conjunctivitis. The drug is available orally in Europe and Asia.
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence…
Treat Guidel Med Lett. 2003 Nov; 1(15):93-100
Allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria and anaphylaxis, along with asthma (reviewed in Treatment Guidelines 2002; 1:7 and not included here), have increased in prevalence during the past 30 years and are now epidemic worldwide, especially in industrialized countries. Many safe and effective drugs are currently available for prevention and relief of symptoms in these disorders, but pharmacological treatment alone may not be sufficient. Patients should also be instructed to avoid specific allergens or environmental conditions that trigger their symptoms. Allergen-specific immunotherapy, parenteral administration of gradually increasing doses of the allergen ("allergy shots"), has been effective in allergic rhinitis, allergic conjunctivitis and allergic asthma, and also in prevention of anaphylaxis triggered by stings from bees, yellow jackets, hornets and wasps. It has not been effective in food allergy, atopic dermatitis or urticaria.
Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of…
Med Lett Drugs Ther. 2003 Mar 17; 45(1152):21-2
Montelukast ( Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma ( Treatment Guidelines from The Medical Letter 2002; 1:11 ), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children more than 2 years old.
The FDA has approved the marketing of loratadine ( Claritin - Schering), a second-generation H 1 -antihistamine, without a prescription. The drug was also recently approved for OTC use as Alavert (Wyeth) and…
Med Lett Drugs Ther. 2003 Jan 6; 45(1147):3-4
The FDA has approved the marketing of loratadine ( Claritin - Schering), a second-generation H 1 -antihistamine, without a prescription. The drug was also recently approved for OTC use as Alavert (Wyeth) and other generics are expected.
Desloratadine (des lor at' a deen; Clarinex - Schering), an active metabolite of the H1-receptor antagonist loratadine ( Claritin ), has been approved by the FDA for oral treatment of allergic rhinitis and…
Med Lett Drugs Ther. 2002 Mar 18; 44(1126):27-8
Desloratadine (des lor at' a deen; Clarinex - Schering), an active metabolite of the H1-receptor antagonist loratadine ( Claritin ), has been approved by the FDA for oral treatment of allergic rhinitis and chronic urticaria in patients at least 12 years old. The patent for loratadine expires in December 2002, and generic or over-the-counter versions are expected.
With the coming of spring, direct-to-consumer (DTC) advertisements in newspapers, in magazines and on television are urging people with seasonal allergies to ask their doctors about one or another of the…
Med Lett Drugs Ther. 2001 Apr 30; 43(1103):35
With the coming of spring, direct-to-consumer (DTC) advertisements in newspapers, in magazines and on television are urging people with seasonal allergies to ask their doctors about one or another of the newer, non-sedating antihistamines.
The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the FDA.
Med Lett Drugs Ther. 1997 Sep 12; 39(1009):86-8
The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the FDA.
Azelastine hydrochloride, a histamine-H1 receptor antagonist, has been marketed as a 0.1% nasal spray ( Astelin - Wallace) for treatment of seasonal allergic rhinitis. Corticosteroid and cromolyn sodium nasal…
Med Lett Drugs Ther. 1997 May 9; 39(1000):45-7
Azelastine hydrochloride, a histamine-H1 receptor antagonist, has been marketed as a 0.1% nasal spray ( Astelin - Wallace) for treatment of seasonal allergic rhinitis. Corticosteroid and cromolyn sodium nasal sprays are also available for this indication (Medical Letter, 37:5, 1995). Cromolyn sodium ( Nasalcrom ) has now been approved for over-the-counter use.
Fexofenadine (fex oh fen' a deen) hydrochloride ( Allegra - Hoechst Marion Roussel) has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis. An active metabolite of…
Med Lett Drugs Ther. 1996 Oct 25; 38(986):95-6
Fexofenadine (fex oh fen' a deen) hydrochloride ( Allegra - Hoechst Marion Roussel) has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis. An active metabolite of terfenadine, fexofenadine is being heavily advertised as "nonsedating...without 'black box' warnings."
Cetirizine (Zyrtec - Pfizer), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis, perennial allergic rhinitis and chronic…
Med Lett Drugs Ther. 1996 Mar 15; 38(970):21-3
Cetirizine (Zyrtec - Pfizer), a histamine H 1 -receptor antagonist, has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria in adults and children more than 12 years old.
The drugs of choice for treatment of deep fungal infections are listed in the table on page 101. Some of the indications and dosages recommended here have not been approved by the US Food and Drug…
Med Lett Drugs Ther. 1996 Feb 2; 38(967):10-2
The drugs of choice for treatment of deep fungal infections are listed in the table on page 101. Some of the indications and dosages recommended here have not been approved by the US Food and Drug Administration. More detailed guidelines are available from the Infectious Diseases Society of America (J Sobel et al, Clin Infect Dis, volume 30, April 2000).
An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal and…
Med Lett Drugs Ther. 1995 Jan 20; 37(940):5-6
An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal and perennial allergic rhinitis in adults and children more than 12 years old.
Acrivastine/Pseudoephedrine ( Semprex-D ) for Seasonal Allergic Rhinitis (Burroughs-Wellcome), a combination of acrivastine with pseudoephedrine hydrochloride, has been approved by the US Food and Drug…
Med Lett Drugs Ther. 1994 Sep 2; 36(930):78-80
Acrivastine/Pseudoephedrine ( Semprex-D ) for Seasonal Allergic Rhinitis (Burroughs-Wellcome), a combination of acrivastine with pseudoephedrine hydrochloride, has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis. Acrivastine is a new H 1 -receptor antagonist with a chemical structure similar to that of triprolidine ( Actidil , and others) (RN Brogden and D McTavish, Drugs, 41:927, 1991). Pseudoephedrine is an α -adrenergic agonist. The combination is available only by prescription.
Loratadine ( Claritin - Schering), a new H 1 -receptor antagonist, has been approved by the U.S. Food and Drug Administration for treatment of seasonal allergic rhinitis in patients more than 12 years old. It…
Med Lett Drugs Ther. 1993 Aug 6; 35(902):71-2
Loratadine ( Claritin - Schering), a new H 1 -receptor antagonist, has been approved by the U.S. Food and Drug Administration for treatment of seasonal allergic rhinitis in patients more than 12 years old. It will compete with older, relatively sedating drugs such as chlorpheniramine ( Chlor-Trimeton , and others) and clemastine ( Tavist - Medical Letter, 35:9, 1993) and with newer relatively non-sedating agents such as terfenadine ( Seldane ) and astemizole (Hismanal).